AnaptysBio, Inc. ANAB
Set alert
47.78 USD +0.87 +1.86%
As of Nov 3, 1:06 PM ET
47.36 Day range 48.35
20.18 52-week range 72.36
- YTD
- +47.84%
- 1 year
- +98.85%
- Open
- 47.36
- Prev close
- 46.91
- Mkt cap
- 1.43B
- Vol
- 77.11K
- Avg vol
- 484.03K
- EPS
- -0.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 47.36
- High
- 48.35
- Forward P/E
- 10.34
- Beta
- 0.37
- Short ratio
- 9.41
- Inst. own
- 105.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 51.76
- 200-d avg
- 50.40
- 1y target
- 87.25
2Y chart
Events in this range
- Aug 7, 2025Earnings: -1.34; estimate -1.5; surprise 10.67%
- Nov 4, 2025Earnings: 0.52; estimate -1.06; surprise 149.06%
- Mar 3, 2026Earnings: 1.58; estimate 0.89; surprise 77.53%
- May 12, 2026Earnings: -1.84; estimate -0.32; surprise -475%
- May 13, 2026Rating: UBS · Buy → Buy
- Aug 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 25, 2026Rating: TD Cowen · Buy → Buy
- Sep 21, 2026Earnings: 5.11; estimate 5.11; surprise 0%
- Sep 23, 2026Rating: Leerink Partners · Outperform → Outperform
- Sep 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 30, 2026Rating: JP Morgan · Overweight → Overweight
- Nov 3, 2026Earnings: —; estimate -1.84; surprise —%
Signals (94)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
Newest 20 of 94.
Key statistics
- Market cap
- 1.40B
- Enterprise value
- 1.55B
- Trailing P/E
- 0.00
- Forward P/E
- 10.34
- PEG ratio
- 0.00
- Price / sales
- 13.22
- Price / book
- 131.77
- EPS (TTM)
- -0.96
- Beta
- 0.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 246.96%
- Revenue (TTM)
- 106.09M
- Revenue growth
- 23.50%
- Free cash flow
- 0
- Total cash
- 164.14M
- Total debt
- 269.59M
- Return on equity
- 0.00%
- Shares outstanding
- 29.90M
- Short % of float
- 39.67%
- 50-day average
- 51.76
- 200-day average
- 50.40
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 87.25 +82.6% upside
Now 47.78
- Target (low)
- 60.00
- Target (mean)
- 87.25
- Target (high)
- 140.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy3
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.53088.
Financials — quick view
ANAB Revenue — quarterly 27.49M
ANAB Net income — quarterly 183.88M
ANAB EPS — quarterly 6.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -1.84 | — | — | — |
| Sep 21, 2026 | Jun 30, 2026 | 5.11 | 5.11 | 0.00 | 0.00% |
| May 12, 2026 | Mar 31, 2026 | -0.32 | -1.84 | -1.52 | -475.00% |
| Mar 3, 2026 | Dec 31, 2025 | 0.89 | 1.58 | +0.69 | +77.53% |
| Nov 4, 2025 | Sep 30, 2025 | -1.06 | 0.52 | +1.58 | +149.06% |
| Aug 7, 2025 | Jun 30, 2025 | -1.50 | -1.34 | +0.16 | +10.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 25, 2026 | TD Cowen | main | Buy | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2026 | UBS | main | Buy | Buy |
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anaptysbio.com
News
- Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
- Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
- AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
- Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
- JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60
- HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
- Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
- AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
- 12 Health Care Stocks Moving In Monday's After-Market Session
- AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate
Your note
Sign in to keep a note on ANAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 1, 2025 | 0 |
| FAGA DANIEL R | Chief Executive Officer | Sale | Mar 26, 2026 | 495,965 |
| JAIN RITA | Director | Conversion of Exercise of derivative security | Jun 12, 2025 | 11,864 |
| LIZZUL PAUL F. | Officer | Sale | Jan 7, 2026 | 42,088 |
| LOUMEAU ERIC JOSEPH | Officer | Sale | Feb 10, 2026 | 12,835 |
| MARQUET MAGDA | Director | Sale | Jan 14, 2026 | 9,930 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 26.36% | 7,880,094 | 369.66M | Jun 29, 2026 |
| Blackrock Inc. | 6.17% | 1,844,049 | 86.50M | Jun 29, 2026 |
| Tang Capital Management, LLC | 4.45% | 1,330,879 | 62.43M | Jun 29, 2026 |
| State Street Corporation | 4.30% | 1,286,194 | 60.34M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.03% | 906,233 | 42.51M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 2.76% | 826,109 | 38.75M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.17% | 648,146 | 30.40M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.14% | 640,363 | 30.04M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.75% | 522,209 | 24.50M | Sep 29, 2026 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.88% | 263,840 | 12.38M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.79% | 237,032 | 11.12M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.72% | 215,873 | 10.13M | Jul 30, 2026 |